Roubaix Capital LLC acquired a new stake in Alpha Teknova, Inc. (NASDAQ:TKNO – Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 416,416 shares of the company’s stock, valued at approximately $2,015,000. Roubaix Capital LLC owned approximately 0.78% of Alpha Teknova at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the business. Conestoga Capital Advisors LLC increased its holdings in Alpha Teknova by 81.6% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 453,899 shares of the company’s stock worth $622,000 after acquiring an additional 203,950 shares in the last quarter. Redmile Group LLC increased its stake in shares of Alpha Teknova by 6.5% during the first quarter. Redmile Group LLC now owns 171,453 shares of the company’s stock worth $434,000 after purchasing an additional 10,448 shares in the last quarter. FourWorld Capital Management LLC acquired a new position in shares of Alpha Teknova during the 1st quarter worth about $135,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in Alpha Teknova in the 1st quarter valued at about $35,000. 13.81% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, Stephens reiterated an “overweight” rating and set a $5.00 price objective on shares of Alpha Teknova in a research note on Wednesday, July 10th.
Alpha Teknova Price Performance
Alpha Teknova stock opened at $7.11 on Thursday. The company has a fifty day simple moving average of $5.24 and a 200-day simple moving average of $3.29. The company has a quick ratio of 3.28, a current ratio of 4.76 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $378.98 million, a price-to-earnings ratio of -7.65 and a beta of 0.43. Alpha Teknova, Inc. has a 52-week low of $1.15 and a 52-week high of $7.49.
Alpha Teknova (NASDAQ:TKNO – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The company had revenue of $9.61 million during the quarter, compared to the consensus estimate of $9.50 million. Alpha Teknova had a negative net margin of 98.08% and a negative return on equity of 37.00%. During the same quarter in the prior year, the firm earned ($0.25) EPS. On average, equities analysts anticipate that Alpha Teknova, Inc. will post -0.54 EPS for the current fiscal year.
Alpha Teknova Profile
Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
Read More
- Five stocks we like better than Alpha Teknova
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
- NYSE Stocks Give Investors a Variety of Quality Options
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.